公开(公告)号：WO2003024443A1

公开(公告)日：2003-03-27

申请号：PCT/US2002/029961

申请日：2002-09-19

Applicant: UNIVERSITY OF FLORIDA ,  MARTYNYUK, Anatoly, E. ,  DENNIS, Donn, Michael ,  GLUSHAKOV, Alexander, V. ,  SUMNERS, Colin ,  PHILLIPS, M., Ian

Inventor： MARTYNYUK, Anatoly, E. ,  DENNIS, Donn, Michael ,  GLUSHAKOV, Alexander, V. ,  SUMNERS, Colin ,  PHILLIPS, M., Ian

IPC: A61K31/195

CPC classification number: A61K31/405 ,  A61K31/198

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinations thereof, and pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combinations thereof.

Abstract translation: 本发明涉及用于治疗与谷氨酸受体（GluR）活性相关或可能受谷氨酸受体（GluR）活性调节的神经学病症的药物组合物，制品和方法。 治疗可以是预防性的或缓解这种神经病症的症状。 本发明的药物组合物包括芳族氨基酸（AAA），AAA的类似物或异构体或其组合，以及药学上可接受的载体或稀释剂。 本发明的方法涉及肠胃外给药至少一种AAA的AAA，类似物或异构体或其组合。

公开(公告)号：WO2006020171A1

公开(公告)日：2006-02-23

申请号：PCT/US2005/025357

申请日：2005-07-18

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. ,  MARTYNYUK, Anatoly, E. ,  DENNIS, Donn, M. ,  GRAVENSTEIN, Nikolaus ,  GLUSHAKOV, Alexander, V. ,  YAROTSKKY, Viktor ,  SUMNERS, Colin ,  SEUBERT, Christoph

Inventor： MARTYNYUK, Anatoly, E. ,  DENNIS, Donn, M. ,  GRAVENSTEIN, Nikolaus ,  GLUSHAKOV, Alexander, V. ,  YAROTSKKY, Viktor ,  SUMNERS, Colin ,  SEUBERT, Christoph

IPC: A61K31/198

CPC classification number: A61K31/198 ,  A61K31/382 ,  A61K31/445 ,  A61K31/505 ,  A61K31/54 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

Abstract: The subject invention pertains to methods of treating mental illnesses or conditions characterized by a decreased function of NMDA receptors and/or excessively enhanced glutamate release and activity of non-NMDA receptors (AMPA and/or kainate). Specifically disclosed are methods utilizing BrPhe, or isomers of analogs thereof, for treating or preventing mental illness or conditions such as schizophrenia.

Abstract translation: 本发明涉及治疗精神疾病或特征在于NMDA受体功能降低和/或过度增强的非NMDA受体（AMPA和/或红藻氨酸）的谷氨酸释放和活性的方法。 具体公开的是使用BrPhe或其类似物的异构体用于治疗或预防精神疾病或诸如精神分裂症的病症的方法。